Patents
Sitemap › C07 - Organic chemistry › C07K - Peptides › C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
Patents for C07K 16 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies (149,320)
08/2012
08/22/2012CN102229915B EV71 virus monoclonal antibody, hybridoma cell line and application
08/22/2012CN101870981B Expression and purification method of heme oxygenase-1, and epitopes thereof
08/22/2012CN101557799B Liquid anti-rabies antibody formulations
08/22/2012CN101460518B Human binding molecules having killing activity against enterococci and staphylococcus aureus and uses thereof
08/22/2012CN101429236B Type II non-structural protein 2B of dengue virus, recombinant expression vector, preparation and uses thereof
08/22/2012CN101072580B Antibody production method
08/21/2012US8247542 T1R3 nucleic acid fragments for use thereof as probes and for generating T1R specific antibodies
08/21/2012US8247537 Human monoclonal antibodies to BTLA and methods of use
08/21/2012US8247534 Synthesis of radiofluorinated peptide using microwave activation technology
08/21/2012US8247225 DNA promoters and anthrax vaccines
08/21/2012US8247194 Preparation of scFv antibody fragments
08/21/2012US8247188 FAS binding antibodies
08/21/2012US8247185 Conformation specific antibodies
08/21/2012US8246958 Methods of inhibiting alpha-4-dependent interactions with VCAM-1 with anti-VLA-4 antibodies
08/21/2012US8246957 Lupus antibodies for passive immunotherapy of HIV/AIDS
08/21/2012US8246956 Humanized anti-nerve growth factor antibodies
08/21/2012US8246955 Substance specific to human PD-1
08/21/2012US8246953 Compositions and methods for use for antibodies against sclerostin
08/21/2012US8246952 Method of increasing radiation sensitivity by inhibition of beta one integrin
08/21/2012CA2633413C Antibodies against tumor-associated antigenic target (tat) polypeptides
08/21/2012CA2607930C Acute leukemia and lymphoblastic lymphoma-specific cd43 epitope and use thereof
08/21/2012CA2579798C Interleukin-15 antagonist peptide
08/21/2012CA2485587C Muteins of placental growth factor type 1, preparation method and application thereof
08/21/2012CA2483848C Antibody against human insulin-like growth factor
08/21/2012CA2480717C Method for producing monoclonal antibodies
08/21/2012CA2449284C Alpha-fetoprotein peptides and uses thereof
08/21/2012CA2428053C Expression of xenogenous (human) immunoglobulins in cloned, transgenic ungulates
08/21/2012CA2364026C Anti-tnf.alpha. antibodies in therapy of asthma
08/21/2012CA2348545C A complex of a chaperone with .beta.-amyloid and methods employing this complex
08/16/2012WO2012109659A1 Hla-restricted, peptide-specific antigen binding proteins
08/16/2012WO2012109569A1 The receptor for advanced glycation endproducts (rage) is a receptor for lysophosphatidic acid (lpa)
08/16/2012WO2012109553A2 Ch2 domain template molecules derived from rational grafting of donor loops onto ch2 scaffolds
08/16/2012WO2012109538A2 Surrogates of post-translationally modified proteins and uses thereof
08/16/2012WO2012109530A1 Pcsk9 antagonists
08/16/2012WO2012109280A2 Apoe immunotherapy
08/16/2012WO2012109133A1 Engineered immunoglobulin fc polypeptides
08/16/2012WO2012108840A1 A novel expression cassette for efficient surface display of antigenic proteins
08/16/2012WO2012108782A1 Antibody that stops or slows tumour growth (variants)
08/16/2012WO2012108650A2 Uses of a monoclonal antibody to proteinase-3 as a therapeutic agent or as a diagnostic agent for a stroke
08/16/2012WO2012108586A1 Method for producing lymphocytes including activated natural killer cells, and pharmaceutical composition including same
08/16/2012WO2012107728A2 Frmd4a antagonists and their uses
08/16/2012WO2012107589A1 Methods and pharmaceutical compositions for the treatment and prevention of hcv infections
08/16/2012WO2012107531A1 B-type plexin antagonists and uses thereof
08/16/2012WO2012107424A1 Anti-gb3 antibodies useful in treating disorders associated with angiogenesis
08/16/2012WO2012107211A1 Anti-alpha-v integrin antibody for the treatment of prostate cancer
08/16/2012WO2012089867A3 Method for selecting cereal seeds suitable for consumption by coeliac patients
08/16/2012WO2012087437A3 Bin1 expression as a marker of skeletal muscle mass and neurological conditions
08/16/2012WO2012085069A3 Detection of a polypeptide dimer by a bivalent binding agent
08/16/2012WO2012071411A3 Nk cell modulating treatments and methods for treatment of hematological malignancies
08/16/2012WO2012068317A3 Methods for producing recombinant proteins
08/16/2012WO2012068236A3 Novel fungal oxidoreductases
08/16/2012WO2012058592A3 Non-antagonistic egfr-binding molecules and immunoconjugates thereof
08/16/2012WO2012054580A3 Polyvalent chimeric ospc vaccinogen and diagnostic antigen
08/16/2012WO2012053828A3 Human interleukin-1 receptor antagonist - hybrid fc fusion protein
08/16/2012WO2012045481A3 Antibody targeting osteoclast-related protein siglec-15
08/16/2012WO2012012531A3 Compositions and methods featuring il-6 and il-21 antagonists
08/16/2012WO2011159928A3 Anti-dr4 agonist antibodies
08/16/2012WO2011091716A9 Epidermal growth factor receptor variant
08/16/2012WO2010055366A4 Anti-human il-21 monoclonal antibodies
08/16/2012US20120210465 Production of Polyunsaturated Fatty Acids, Novel Biosynthesis Genes, And Novel Plant Expression Constructs
08/16/2012US20120208987 Barriers for facilitating biological reactions
08/16/2012US20120208986 Use of mixed mode chromatography for the capture and purification of basic antibody products
08/16/2012US20120208985 Motif-Specific and Context-Independent Antibodies That Specifically Bind to a Cleaved Caspase Motif or a Sumoylated Lysine-Containing Motif
08/16/2012US20120208984 Humanized anti-beta7 antagonists and uses therefor
08/16/2012US20120208983 Methods, devices, kits and compositions for detecting whipworm
08/16/2012US20120208774 Method for inhibiting "melanoma inhibitory activity" mia
08/16/2012US20120208295 Methods and compositions for mass spectrometry analysis
08/16/2012US20120208294 Immunodetection and quantification of pyrazolopyrimidine sedatives
08/16/2012US20120208270 POLY-N-ACETYL GLUCOSAMINE (PNAG/dPNAG)-BINDING PEPTIDES AND METHODS OF USE THEREOF
08/16/2012US20120208238 Engineered immunoglobulin fc polypeptides
08/16/2012US20120208234 Protein having affinity for immunoglobulin, and immunoglobulin-binding affinity ligand
08/16/2012US20120208216 Non-cross-reactive anti igg antibodies
08/16/2012US20120208213 Detection of Synthetic Cannabinoids
08/16/2012US20120207778 Nucleic acids and proteins from streptococcus groups a and b
08/16/2012US20120207772 Anti-muc1 alpha/beta antibodies
08/16/2012US20120207770 Antiproliferative agent
08/16/2012US20120207761 Anti-il-22ra antibodies and binding partners and methods of using in inflammation
08/16/2012US20120207759 Compositions and methods for modulating lymphocyte activity
08/16/2012US20120207758 CD22 Exon 12 Deletion Mutants
08/16/2012US20120207755 Cancer
08/16/2012US20120207750 Antibodies against human tweak and uses thereof
08/16/2012US20120207746 Anti-C epsilon mX antibodies capable of binding to human mIgE on B Lymphocytes
08/16/2012US20120207711 Infectivity-enhanced conditionally-replicative adenovirus and uses thereof
08/16/2012US20120207673 Modified Variable Domain Molecules And Methods For Producing And Using Same
08/16/2012US20120207672 Selective detection of bone metastases in renal clear cell carcinoma
08/16/2012CA2841404A1 Treatment of angiogenesis disorders
08/16/2012CA2827091A1 Pcsk9 antagonists
08/16/2012CA2827052A1 Anti-alpha-v integrin antibody for the treatment of prostate cancer
08/16/2012CA2827017A1 B-type plexin antagonists and uses thereof
08/16/2012CA2826942A1 Hla-restricted, peptide-specific antigen binding proteins
08/16/2012CA2826566A1 Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
08/16/2012CA2826564A1 Treatment of osteoarthritis and pain
08/16/2012CA2826563A1 Methods and systems for treating or preventing pregnancy-related hypertensive disorders
08/16/2012CA2826467A1 Engineered immunoglobulin fc polypeptides
08/16/2012CA2826020A1 Surrogates of post-translationally modified proteins and uses thereof
08/16/2012CA2825791A1 Apoe immunotherapy
08/15/2012EP2487190A2 Single-domain antigen-binding proteins that bind mammalian IgG
08/15/2012EP2487189A1 Monoclonal antibodies for treatment of cancer
08/15/2012EP2487188A2 IL-17 receptor A antigen binding proteins
08/15/2012EP2487187A2 Human cytomegalovirus neutralising antibodies and use thereof
1 ... 172 173 174 175 176 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 ... 1494